Atreca, Inc., a Redwood City, CA-based biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, completed its $56m Series A funding.
The round was led by a large U.S.-based, healthcare-focused fund with participation from the Bill & Melinda Gates Foundation, Mission Bay Capital, and GlaxoSmithKline.
The company intends to use the funds for the further development and advancement of its product pipeline, including therapeutic antibodies designed to optimize anti-tumor immune responses in synergy with checkpoint inhibitors and immune activators.
Led by Dr. Tito Serafini, Chief Executive Officer and Co-Founder, Atreca develops novel therapeutics drawn from human immune responses, including effective anti-cancer immune responses. Its proprietary Immune Repertoire Capture™ technology profiles a patient’s immune response at the single-cell level at very high throughput without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen.